CRESCITA THERAPEUTICS INC (CTX.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:CTX - CA2258471028 - Common Stock
CTX.CA Key Statistics, Chart & Performance
The current stock price of CTX.CA is 0.465 CAD. In the past month the price decreased by -1.06%. In the past year, price decreased by -16.96%.
CTX.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.88 | 3.65B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.61B | ||
| CRON.CA | CRONOS GROUP INC | 25.07 | 1.44B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.11 | 881.76M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 655.86M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 592.76M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 528.16M | ||
| TSND.CA | TERRASCEND CORP | N/A | 405.08M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 16.78 | 383.09M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 352.50M | ||
| HITI.CA | HIGH TIDE INC | N/A | 339.40M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 323.74M |
Related stock screener links
About CTX.CA
Company Profile
Crescita Therapeutics, Inc. engages in the provision of non-prescription skincare products. The company is headquartered in Laval, Quebec and currently employs 75 full-time employees. The company went IPO on 2016-03-07. The company offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. The company operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. The company also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment is engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. The Manufacturing and Services segment is engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.
Company Info
CRESCITA THERAPEUTICS INC
2805, Place Louis R Renaud
Laval QUEBEC H7V 0A3 CA
CEO: Serge Verreault
Employees: 75
Phone: 18003610352
CRESCITA THERAPEUTICS INC / CTX.CA FAQ
What does CRESCITA THERAPEUTICS INC do?
Crescita Therapeutics, Inc. engages in the provision of non-prescription skincare products. The company is headquartered in Laval, Quebec and currently employs 75 full-time employees. The company went IPO on 2016-03-07. The company offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. The company operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. The company also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment is engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. The Manufacturing and Services segment is engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.
Can you provide the latest stock price for CRESCITA THERAPEUTICS INC?
The current stock price of CTX.CA is 0.465 CAD.
Does CRESCITA THERAPEUTICS INC pay dividends?
CTX.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of CTX stock?
CTX.CA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the number of employees for CRESCITA THERAPEUTICS INC?
CRESCITA THERAPEUTICS INC (CTX.CA) currently has 75 employees.
Can you provide the upcoming earnings date for CRESCITA THERAPEUTICS INC?
CRESCITA THERAPEUTICS INC (CTX.CA) will report earnings on 2026-03-16.
CTX.CA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CTX.CA. When comparing the yearly performance of all stocks, CTX.CA is a bad performer in the overall market: 84.62% of all stocks are doing better.
CTX.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CTX.CA. No worries on liquidiy or solvency for CTX.CA as it has an excellent financial health rating, but there are worries on the profitability.
CTX.CA Financial Highlights
Over the last trailing twelve months CTX.CA reported a non-GAAP Earnings per Share(EPS) of 0.02. The EPS increased by 117.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2.07% | ||
| ROA | 2.13% | ||
| ROE | 2.81% | ||
| Debt/Equity | 0 |